Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Contact Supplier

Jai Radhe Sales is your partner for all your sourcing needs.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

2 API Suppliers, 2 USDMF

2 API Suppliers
2 USDMF

DEVELOPMENTS

4 Drugs in Development

4 Drugs in Development

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

4DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 197904-84-0, Tg01, Cs-706, Tg-01, R-109339, 5x5hb3vz3z

Molecular Formula

C₁₉H₂₀N₂O₃S

Molecular Weight

356.4 g/mol

InChI Key

JTMITOKKUMVWRT-UHFFFAOYSA-N

FDA UNII

5X5HB3VZ3Z

Apricoxib is an orally bioavailable nonsteroidal anti-inflammatory agent (NSAID) with potential antiangiogenic and antineoplastic activities. Apricoxib binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), thereby inhibiting the conversion of arachidonic acid into prostaglandins. Apricoxib-mediated inhibition of COX-2 may induce tumor cell apoptosis and inhibit tumor cell proliferation and tumor angiogenesis. COX-related metabolic pathways may represent crucial regulators of cellular proliferation and angiogenesis.

1 2D Structure

Apricoxib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

4-[2-(4-ethoxyphenyl)-4-methylpyrrol-1-yl]benzenesulfonamide

2.1.2 InChI

InChI=1S/C19H20N2O3S/c1-3-24-17-8-4-15(5-9-17)19-12-14(2)13-21(19)16-6-10-18(11-7-16)25(20,22)23/h4-13H,3H2,1-2H3,(H2,20,22,23)

2.1.3 InChI Key

JTMITOKKUMVWRT-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CCOC1=CC=C(C=C1)C2=CC(=CN2C3=CC=C(C=C3)S(=O)(=O)N)C

2.2 Other Identifiers

2.2.1 UNII

5X5HB3VZ3Z

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 2-(4-ethoxyphenyl)-4-methyl 1-(4-sulfamoylphenyl)-1h-pyrrole

2. Cs 706

3. Cs-706

4. Cs706 Cpd

2.3.2 Depositor-Supplied Synonyms

1. 197904-84-0

2. Tg01

3. Cs-706

4. Tg-01

5. R-109339

6. 5x5hb3vz3z

7. 4-[2-(4-ethoxyphenyl)-4-methylpyrrol-1-yl]benzenesulfonamide

8. 4-(2-(4-ethoxyphenyl)-4-methyl-1h-pyrrol-1-yl)benzenesulfonamide

9. Cs 706; R 109339; Tg 01

10. Benzenesulfonamide, 4-(2-(4-ethoxyphenyl)-4-methyl-1h-pyrrol-1-yl)-

11. Apricoxib [usan]

12. Apricoxib [usan:inn]

13. Unii-5x5hb3vz3z

14. Capoxigem

15. Kymena

16. Tg 01

17. Cs 706

18. Apricoxib [inn]

19. Apricoxib (usan/inn)

20. Cs706 Cpd

21. Apricoxib [who-dd]

22. Schembl346028

23. R 109339

24. Chembl1835207

25. Dtxsid60173502

26. Cs701

27. Db12378

28. Tp-1001

29. Tp-2001

30. D08657

31. Q18209480

32. 2-(4-ethoxyphenyl)-4-methyl-1-(4-sulfamoylphenyl)pyrrole

33. 4-methyl-2-(4-ethoxyphenyl)-1-(4-sulfamoylphenyl)pyrrole

34. 2-(4-ethoxyphenyl)-4-methyl 1-(4-sulfamoylphenyl)-1h-pyrrole

2.4 Create Date

2006-10-25

3 Chemical and Physical Properties

Molecular Formula	C₁₉H₂₀N₂O₃S
Molecular Weight	356.4 g/mol
XLogP3	3.2
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	4
Rotatable Bond Count	5
Exact Mass	356.11946368 g/mol
Monoisotopic Mass	356.11946368 g/mol
Topological Polar Surface Area	82.7 Å²
Heavy Atom Count	25
Formal Charge	0
Complexity	517
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1